# Sermorelin vs Tesamorelin: GHRH Analogs in Body-Composition Research > Sermorelin vs tesamorelin: two GHRH analogs, one native and short-acting, one stabilized and approved for HIV lipodystrophy. The structural, pharmacokinetic, and body-composition differences, cited. Same receptor, different build. The native short-acting fragment beside the stabilized, longer-lasting analog — what each is, what each was studied for, and where the body-composition evidence actually lives. ## The short version **Sermorelin vs tesamorelin** is a comparison of two molecules that pull the same lever — the GHRH receptor (the pituitary's "make growth hormone" switch) — but are built differently. Sermorelin is the short native fragment, GHRH(1-29), cleared from blood in minutes. Tesamorelin is a stabilized, longer-lasting GHRH analog that resists the enzymes that chew up the native peptide. The practical difference shows up in the evidence: the strongest belly-fat (visceral-fat) data in this drug class come from tesamorelin trials, while sermorelin's firmest record is in childhood growth and the adult growth-hormone axis. This page keeps those lanes separate so a tesamorelin finding is never mistaken for a sermorelin one. ## Two GHRH analogs, one receptor Both sermorelin and tesamorelin are growth hormone-releasing hormone analogs that act on the same GHRH receptor on pituitary somatotrophs, stimulating the body's own GH release with feedback preserved [13]. They are members of the same mechanistic family, not rivals with different targets. Each works upstream — a trigger for the gland rather than a supply of hormone — so both leave somatostatin and IGF-1 feedback intact and both preserve the natural pulsatile pattern of GH secretion [4]. The difference is structural. Sermorelin is the amidated native 1-29 fragment of GHRH — the shortest fully active piece, and a short-half-life molecule by nature [3]. Tesamorelin is a stabilized synthetic GHRH analog engineered for protease resistance and a longer functional effect, which is what made it viable as a once-daily approved therapy in its indication. Put simply: the receptor and the downstream pulse are shared; the molecule's durability in the body is not. ## Pharmacokinetics: short native fragment vs stabilized analog The pharmacokinetic contrast is the practical heart of **sermorelin vs tesamorelin**. Sermorelin clears from plasma in about 10-12 minutes, though a single dose still elevates GH for roughly 3 hours [3]. That short plasma life is typical of small unprotected peptides, which are cleaved quickly by circulating peptidases. Its brevity is the reason the field engineered longer-acting analogs in the first place — see [sermorelin half-life](/half-life). Tesamorelin's stabilization gives it a longer functional window, supporting sustained daily dosing in trials measuring weeks-to-months endpoints [6][9]. The two molecules therefore differ less in *what* they do per pulse than in *how durably* they keep doing it. Same receptor, same feedback-preserving mechanism; a meaningfully longer effective duration on the tesamorelin side. This is the same engineering logic that produced the other long-acting GHRH analogs — a D-Ala2-type substitution to resist enzymatic cleavage, or an albumin-binding complex to tether the peptide to a long-circulating carrier. ## Where the body-composition evidence lives This is the distinction that matters most for honest reading. The drug-class **body-composition** evidence is concentrated on the tesamorelin side. In HIV-infected patients with abdominal fat accumulation, tesamorelin significantly reduced visceral adipose tissue versus placebo [9]; a randomized trial in HIV-infected men with lipodystrophy evaluated the same axis on fat distribution [10]; and the 152-adult GHRH-analog trial reported IGF-1 +117% and percent body fat -7.4% over 20 weeks [6]. Those are specific, randomized, placebo-controlled measurements — but they belong to the stabilized analog, not to GHRH(1-29). Sermorelin's own firmest evidence is in childhood growth — first-year height velocity from about 4.1 to 7-8 cm/year [1], with the growth-velocity signal extending even to short children with normal GH secretion [8] — and in the adult GH/IGF-1 axis, where it reversed age-related declines in older men [2]. The mechanistic link between the two records is the GH/IGF-1 axis itself: visceral fat is not a passive bystander to GH secretion. In 47 men studied under combined GHRH and GHRP-2, abdominal visceral fat, IGF-1 and IGFBP-3 together explained 60% of the variability in the GH response, visceral fat negatively associated [7]. So the body-composition story is biologically continuous across the class. But when body-composition *claims* are made for "sermorelin" specifically, they are usually leaning on the tesamorelin trial record. That borrowing should be stated, not blurred — which is the entire reason this comparison page keeps the two molecules in separate columns. ## What each was studied for The two molecules carry different research records, and conflating them is the most common error in popular summaries. Sermorelin's strongest evidence is developmental and adult-axis: accelerated growth in growth-hormone-deficient children [1], growth-velocity gains in short children with normal GH secretion [8], and reversal of the age-related GH/IGF-1 decline in older men [2]. Tesamorelin's record is built around body composition. Its visceral-fat reduction versus placebo in HIV-associated fat accumulation is the anchor finding [9]; a randomized trial in HIV-infected men with lipodystrophy examined the same axis [10]; and the 152-adult GHRH-analog trial that reported IGF-1 +117% and percent body fat -7.4% over 20 weeks used the tesamorelin-class molecule, not sermorelin [6]. So when a body-composition claim is attached to "sermorelin," check whether the underlying study actually used GHRH(1-29) or the stabilized analog. Usually it is the latter. ## Regulatory framing: both honestly stated Both molecules have specific, often-misstated regulatory histories. Sermorelin was FDA-approved for pediatric growth-hormone deficiency (NDA 020443) and withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy — and is now compounded as a Category 1 bulk drug substance under FDA's Section 503A framework [5]. Tesamorelin is a currently FDA-approved drug, but approved only for a single indication: HIV-associated lipodystrophy. Neither molecule is approved as an anti-aging or general weight-loss therapy, and the body-composition findings above sit outside both molecules' approved-or-formerly-approved uses. Both are prohibited in sport under the WADA growth-hormone-secretagogue category (S2), and dedicated detection methods for GHRH analogs exist. This site describes the research record only and gives no human dosing for either compound. --- The GHRH(1-29) record stencilled onto raw concrete — the pulsatile-GH mechanism, the studied doses, the body-composition data filed where it belongs as tesamorelin, the formerly-approved-then-withdrawn history set straight, and the thin adult-safety line sprayed in caution-orange; no clinic behind the wall and nothing here dosed, compounded, or sold.